Enbrel is an injection that helps with various inflammatory diseases. It is indicated for the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It is a tumor necrosis factor (TNF) blocker with the active ingredient etanercept. The original manufacturer of this product was Immunex Corporation. However, due to an acquisition, the current manufacturer is Amgen Inc.
What is it made of?
Enbrel is formulated as a sterile, clear and colorless, preservative-free solution. The active ingredient is etanercept. Etanercept is produced by recombinant deoxyribonucleic acid (DNA) technology. It is a TNF blocker that is a dimeric fusion protein. It consists of the extracellular ligand-binding portion of the tumor necrosis factor receptor.
What are its uses?
Enbrel helps to stop structural damage progression, improve physical function, and induce clinical response. It reduces signs and symptoms of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.
How long do its effects last?
Studies show the half-life of this product to be approximately 102 hours and clearance approximately 160ml/hr for rheumatoid arthritis patients administered a single injection of 25mg of Enbrel. As well, it has been shown that serum concentration profiles at steady-state were comparable among patients treated with 50mg once weekly and those treated with 25mg twice weekly.